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ABSTRACT
One of the factors causing treatment failure in cryptococcosis is the resistance of 
Cryptococcus spp. to antifungal drugs, which has motivated the susceptibility assessment 
of isolates from patients with cryptococcosis, different clinical conditions and infections 
outcomes. Clinical isolates of Cryptococcus spp. from three different groups of patients 
were studied in the present investigation: 19 HIV-positive patients with relapsing and/or 
refractory meningitis (Group 1), 30 HIV-positive patients who experienced a single and 
limited episode of cryptococcosis (Group 2), and 19 HIV-negative patients with cryptococcosis 
(Group 3). Eighty C. neoformans var. grubii isolates and 7 C. gattii isolates were studied. 
The minimum inhibitory concentration (MIC) of amphotericin B, azole drugs and flucytosine 
was determined for Cryptococcus spp. by broth microdilution test and E-test. The MIC50 and 
MIC90 were 0.25 and 0.50 µg/mL for amphotericin B, 4.0 and 8.0 µg /mL for fluconazole, 
0.06 and 0.25 µg/mL for itraconazole, 0.25 and 0.50 µg/mL for voriconazole, and 8.0 and 
16.0 µg/mL for flucytosine, respectively. Amphotericin B and itraconazole showed higher 
MICs for C. neoformans var. grubii and C. gattii, respectively. The MICs of fluconazole and 
itraconazole obtained with the E-test were higher than those obtained with broth microdilution. 
Isolates from non-HIV coinfected were less sensitive to the azoles. There was no difference 
in the susceptibility of C. neoformans var. grubii isolates from patients with a favorable or 
unfavorable outcome or along the episodes of relapsing and/or refractory meningitis.
KEYWORDS: Cryptococcal meningitis. Relapsing and refractory cryptococcosis. 
Cryptococcus spp. Antifungal susceptibility. HIV.
INTRODUCTION
Cryptococcosis is the second most frequent systemic fungal infection involving 
HIV-positive patients. It occurs also in other immunosuppression conditions and 
in immunocompetent individuals1. The lethality of cryptococcosis is high even 
with the use of antifungal drugs. In refractory and/or relapsing cases, neurological 
sequelae frequently occur in survivors. Cryptococcus neoformans var. grubii and 
C. gattii are commonly isolated from patients and the most common manifestation is 
cryptococcal meningitis, occurring in 90% of the cases2. Cryptococcus spp. usually 
shows susceptibility to amphotericin B, azole drugs and flucytosine3,4. Amphotericin 
B in combination with flucytosine is recommended for the treatment of cryptococcal 
meningitis, followed by maintenance therapy with fluconazole2. At present, the 
resistance of Cryptococcus spp. to amphotericin B, fluconazole and flucytosine is 
less than 1%, but non-susceptible strains have arisen all over the world, suggesting 
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progression to a future broader resistance5,6. The lack of 
susceptibility of Cryptococcus spp. to these antifungal agents 
may be one of the critical factors determining an adverse 
outcome in patients with cryptococcosis7. The assessment of 
antifungal Cryptococcus spp. susceptibility is recommended 
in order to plan patient treatment and also to monitor the 
tendency of resistance to drugs used in clinical practice. 
In the present study, previously genotyped isolates8 of 
C. neoformans var. grubii and C. gattii were used in order 
to assess antifungal drugs susceptibility by comparing 
the broth microdilution test with the E-test among the 
Cryptococcus species isolated from HIV-negative and 
HIV-positive, the latter group according to the outcome.
MATERIALS AND METHODS
Clinical isolates
A total of 87 Cryptococcus spp. isolates from 68 patients 
with cryptococcal meningitis were evaluated. The patients 
were diagnosed and treated at the University Hospital, 
Ribeirão Preto Medical School, University of São Paulo, 
Ribeirão Preto, SP, Brazil, from 2000 to 2011. For the 
comparison of antifungal susceptibility of the isolates, the 
patients were divided into three groups. Group 1 consisted 
of the isolates from 19 immunocompromised HIV-positive 
patients with relapsing and/or refractory cryptococcosis 
(a total of 38 isolates, 19 of which corresponded to the 
initial episode of cryptococcosis and 19 to the refractory 
or relapse period). The refractory or relapse period was 
defined as the reisolation of Cryptococcus spp. from 
cerebrospinal fluid (CSF) after a period of negative cultures 
or as the persistence of isolation of Cryptococcus spp. 
from CSF after two months of antifungal therapy. Group 
2 consisted of 30 isolates (CSF collected before antifungal 
treatment) from 30 immunocompromised HIV-positive 
patients who had experienced a single and limited episode 
of cryptococcosis. Group 3 consisted of 19 Cryptococcus 
spp. isolates from apparently immunocompetent (11 cases) 
or immunocompromised HIV-negative patients (8 cases) 
(in all patients, the CSF was collected before antifungal 
treatment). The eventual change of C. neoformans var. grubii 
susceptibility was checked in refractory or relapsing cases 
(Group 1) by comparing the first isolate obtained during the 
pretreatment phase to the last isolate obtained from each 
patient after treatment failure (2 to 87 month interval between 
the isolates). The lethality of cryptococcosis was analyzed 
according to C. neoformans susceptibility in 23 patients 
with AIDS (Groups 1 and 2) treated with amphotericin B 
for at least one month followed by maintenance therapy 
with fluconazole. For the outcome analysis, we considered 
the deaths attributed to complications of cryptococcosis, 
including bacterial infections that occurred during the 
induction and consolidation phase and late deaths in cases of 
relapsing and/or refractory cryptococcal infection.
Microorganisms and growth conditions
Cryptococcus spp. isolates were previously identified 
by standard Clinical Mycology methods and also using 
the automated system Vitek® 1 or Vitek® 2 (bioMérieux, 
France) and by using molecular methods8. The yeasts were 
maintained in the laboratory by periodic culture in Sabouraud 
Dextrose Agar (SDA) medium at 25 °C. A total of 87 
Cryptococcus spp. isolates were studied, -80 C. neoformans 
var. grubii isolates were distributed among group 1 (n= 38), 
group 2 (n=29), and group 3 (n=13). C. gattii (n=7) were 
identified in group 2 (n=1) and group 3 (n=9).
Antifungal susceptibility testing
Broth microdilution
The susceptibility of Cryptococcus spp. isolates to the 
antifungal drugs was determined by the broth microdilution 
method according to the M27-A2 protocol (Clinical and 
Laboratory Standards Institute)9. Roswell Park Memorial 
Institute (RPMI) medium 1640 (Sigma Aldrich Chemical 
Company, St Louis, MO) containing L-glutamine buffer 
with 2% glucose added and buffered with morpholino 
propanesulfonic acid (MOPS) and 1 M NaOH, pH 7.0, was 
added to sterile 96-well flat-bottom plates (TPP, Switzerland). 
The yeast inoculum was prepared in RPMI culture medium to 
a final concentration of 2.0 x 103 CFU mL-1, as recommended 
by the M27-A29 document.
The antifungal drugs tested were: amphotericin B, 
fluconazole, itraconazole, voriconazole, and flucytosine 
(Sigma Aldrich Chemical Corporation). Amphotericin B, 
itraconazole and voriconazole were diluted in dimethyl 
sulfoxide (Sigma Aldrich Chemical Corporation), while 
fluconazole and flucytosine were dissolved in sterile 
distilled water. The antifungal drugs were diluted in RPMI 
medium and serial dilutions were carried out in order 
to obtain final concentrations of 0.125-64 µg mL-1 for 
flucytosine, 0.125- 64 µg mL-1 for fluconazole and 0.03-16 
µg mL-1 for amphotericin B, itraconazole and voriconazole. 
The 96-well plates were incubated at 37 °C for 48 h 
and the optical density of each well was measured with a 
microplate reader (Multiskan MS) adjusted to a wavelength 
of 492 nm. The minimum inhibitory concentration (MIC) 
was considered as the lowest concentration capable of 
inhibiting fungal growth by ≥ 80% for amphotericin B 
and by ≥ 50% for the other antifungal drugs in relation 
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to the positive control (CLSI, 2002)9. The instrumental 
reading was confirmed by visual reading. C. neoformans 
ATCC 90112 and Candida parapsilosis ATCC 22019 were 
included in all tests as positive controls. The MIC values for 
all drugs were interpreted according to the CLSI M27-A2 
protocol. The susceptibility of each Cryptococcus spp. 
isolate was determined in duplicate.
E-test
E-test was performed according to the manufacturer’s 
instructions (AB Biodisk – Solna, Sweden). The antifungal 
drugs tested were itraconazole, fluconazole, voriconazole 
and amphotericin B. The medium used was RPMI 1640 
containing 1.5% agar, supplemented with 2% glucose and 
buffered with MOPS to pH 7. The yeast inoculum was the 
same used for the broth microdilution. E-test gradient strips 
were placed on the surface of a previously inoculated plate 
by seeding the inoculum on the surface of the agar plate and 
left to dry for 15 min. The E-test strips had the following 
gradient of antifungal concentration: 0.002-32.0 µg mL-1 
for amphotericin B, itraconazole and voriconazole and 
0.016-256 µg mL-1 for fluconazole. The plates were 
incubated at 37 °C for 48 h. MIC readings were obtained 
at the point of intersection between the ellipse of growth 
inhibition and the E-test strip.
Statistical analysis
The Excel 2007 for Windows software (Microsoft 
Corp., USA) was used to determine the MIC50 and MIC90 
values and the geometric mean. The data for groups 1, 2 
and 3 were compared by the Kruskal-Wallis test and the 
Dunn’s post-hoc test. The methods (broth microdilution and 
E-test), the data for the species (C. neoformans var. grubii 
and C. gattii) and the data for patient outcome (cure and 
death) were compared by the Mann-Whitney test using the 
GraphPad Prism 6 software (San Diego, CA). The level of 
significance was set at p< 0.05 in all analysis.
Ethics considerations
The study was approved by the Research Ethics 
Committee of the University Hospital, Ribeirão Preto 
Medical School, University of São Paulo (Protocol HCRP 
n° 12247/2010).
RESULTS
Comparison of broth microdilution and E-test methods
Four antifungal drugs were tested by broth microdilution 
method and E-test against 61 clinical isolates of C. 
neoformans var. grubii belonging to groups 1, 2 and 3. 
E-test MICs were higher for fluconazole and itraconazole. 
In contrast, the MICs for amphotericin B and voriconazole 
were higher in broth microdilution method (p< 0.0001) 
(Table 1). 
In vitro susceptibility of C. neoformans var. grubii and 
C. gattii comparison
Five antifungal drugs were tested by the broth 
microdilution method in 61 clinical isolates of C. 
neoformans var. grubii and in 7 isolates of C. gattii. C. 
neoformans var. grubii was less susceptible to amphotericin 
B (P = 0.0004), while C. gattii was less susceptible to 
itraconazole (P = 0.0114) (Table 2).
Comparison of in vitro susceptibility of C. neoformans 
var. grubii according to the patient’s group
A significant MIC difference was detected for 
itraconazole (P = 0.0186) and voriconazole (p = 0.0022) 
on in vitro susceptibility test. The Dunn’s post-test showed 
that this significant difference was between Group 1 and 
Group 3 for itraconazole and between Group 2 and Group 3 
for voriconazole (Figure 1). 
MIC of the antifungal drugs and outcome
C. neoformans var. grubii showed similar susceptibility 
to amphotericin B (p = 0.2227) and to fluconazole 
(p = 0.1729) in patients with AIDS (Group 1 and 2) whose 
outcome was death (n=6) or progression to cure (n = 17) 
(Figure 1). C. neoformans var. grubii isolated at the 
beginning of the treatment and after treatment failure in 
patients with AIDS and refractory/relapsing cryptococcosis 
(group 1) have shown no differences in susceptibility to the 
five antifungal drugs tested (Table 3). 
DISCUSSION
The most relevant result obtained in the present study 
was that there was no association between progression to 
relapsing/refractory cryptococcosis in patients with AIDS 
and the MICs of C. neoformans for antifungal drugs. Study 
limitations were the reduced number of C. gattii-infected 
patients and the small number of cases included in the 
analysis of the impact of antifungal MIC distribution with 
respect to the cure vs. death outcome.
As previously observed10, C. gattii was less susceptible 
to azole drugs than C. neoformans var. grubii. For this 
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Table 1 - Comparative assessment of the antifungal MICs obtained by the broth microdilution method and by the E-test for C. 
neoformans var. grubii isolates (61 isolates)
Antifungal Drug
Susceptibility test 
Broth Microdilution E-test p value***
Amphotericin B MIC Range (µg/mL) 0.13 - 0.50 0.047 - 0.50 < 0.0001
MIC 50 (µg/mL)* 0.25 0.19
MIC 90 (µg/mL)* 0.50 0.38
G.M (µg/mL)** 0.30 0.20
Fluconazole MIC Range (µg/mL) 1.0 - 16.0 0.125 - 32.0 < 0.0001
MIC 50 (µg/mL) 4.0 12.0
MIC 90 (µg/mL) 8.0 16.0
G.M (µg/mL) 4.67 12.60
Itraconazole MIC Range (µg/mL) 0.03 - 1.0 0.016 - 2.0 < 0.0001
MIC 50 (µg/mL) 0.06 0.38
MIC 90 (µg/mL) 0.25 0.75
G.M (mg/L) (µg/mL) 0.13 0.44
Voriconazole MIC Range (µg/mL) 0.03 - 0.50 0.016 - 0.75 < 0.0001
MIC 50 (µg/mL) 0.25 0.094
MIC 90 (µg/mL) 0.50 0.25
G.M (µg/mL) 0.27 0.14
* MIC50 and MIC90. the concentration capable of inhibiting the growth of 50% and 90% of the isolates, respectively.**GM: geometric 
mean, ***p value, statistic.
Table 2 - Comparison of the in vitro antifungal susceptibility of C. neoformans var. grubii (n= 61) and C. gattii (n = 7) by the broth 
microdilution methods
Antifungal Drug
Broth Microdilution
C. neoformans var.grubii C. gattii p value***
Amphotericin B MIC Range (µg/mL) 0.13 - 0.50 0.06 - 0.50 0.0004
MIC 50 (µg/mL)* 0.25 0.06
MIC 90 (µg/mL)* 0.50 0.13
G.M (µg/mL)** 0.30 0.14
Fluconazole MIC Range (µg/mL) 1.0 - 16.0 2.0 - 16.0 0.1139
MIC 50 (µg/mL) 4.0 8.0
MIC 90 (µg/mL) 8.0 8.0
G.M (µg/mL) 4.67 7.14
Itraconazole MIC Range (µg/mL) 0.03 - 1.0 0.13 - 0.25 0.0114
MIC 50 (µg/mL) 0.06 0.13
MIC 90 (µg/mL) 0.25 0.25
G.M (µg/mL) 0.13 0.16
Voriconazole MIC Range (µg/mL) 0.03 - 0.50 0.25 - 0.50 0.0758
MIC 50 (µg/mL) 0.25 0.50
MIC 90 (µg/mL) 0.50 0.50
G.M (µg/mL) 0.27 0.39
Flucytosine MIC Range (µg/mL) 4.0 - 16.0 4.0 - 16.0 0.7630
MIC 50 (µg/mL) 8.0 8.0
MIC 90 (µg/mL) 16.0 16.0
G.M (µg/mL) 8.19 7.42
* MIC50 and MIC90 are the concentrations capable of inhibiting the growth of 50% and 90% of the isolates, respectively, **GM: 
geometric means, ***p value, statistic.
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Table 3 - Antifungal susceptibility of C. neoformans var. grubii isolates obtained before treatment and during the period refractory 
to treatment or during relapse of cryptococcosis from 19 patients with AIDS
Antifungal Drug
GROUP 1
Pretreatment Relapse and/or refractory period p value***
Amphotericin B MIC Range (µg/mL) 0.13 - 0.50 0.13 - 0.50 0.8791
MIC 50 (µg/mL)* 0.25 0.25
MIC 90 (µg/mL)* 0.50 0.50
G.M (µg/mL)** 0.28 0.27
Fluconazole MIC Range (µg/mL) 1.0 - 8.0 0.13 - 8.0 0.6290
MIC 50 (µg/mL) 4.0 4.0
MIC 90 (µg/mL) 4.0 8.0
G.M (µg/mL) 3.84 3.64
Itraconazole MIC Range (µg/mL) 0.03 - 1.0 0.03 - 0.13 0.1973
MIC 50 (µg/mL) 0.06 0.06
MIC 90 (µg/mL) 0.25 0.13
G.M (µg/mL) 0.13 0.08
Voriconazole MIC Range (µg/mL) 0.03 - 0.50 0.25 - 0.50 0.6102
MIC 50 (µg/mL) 0.25 0.25
MIC 90 (µg/mL) 0.50 0.50
G.M (µg/mL) 0.30 0.27
Flucytosine MIC Range (µg/mL) 4.0 - 16.0 4.0 - 16.0 0.4888
MIC 50 (µg/mL) 8.0 8.0
MIC 90 (µg/mL) 16.0 8.0
G.M (µg/mL) 7.78 6.63
* MIC50 and MIC90. the concentrations capable of inhibiting the growth of 50% and 90% of the isolates, respectively, **GM: geo-
metric means, ***p value, statistic.
Figure 1 - Comparison of the in vitro susceptibility of C. neoformans var. grubii isolates from group 1 (n=19), 2 (n=29) and 3 
(n=13) patients to the antifungal agents amphotericin B (A), fluconazole (B), itraconazole (C), voriconazole (D) and flucytosine (E) 
by the broth microdilution method. The bars show the mean of the minimum inhibitory concentrations. The p-values obtained are 
represented in the graphs
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reason and because of the small number of C. gattii isolates, 
only the MICs obtained for C. neoformans var. grubii 
were related to other clinical and laboratory data. When 
comparing the methods, higher MIC values for fluconazole 
and itraconazole were obtained with the E-test than with the 
CLSI-broth microdilution standardized test9. Discordance 
for azoles has been detected in other studies and has been 
known since the first determinations of the fluconazole 
MIC for C. neoformans with the E-test11,12. More recently, 
high concordance was observed between the two methods 
regarding the MIC of azole drugs5. Regarding amphotericin 
B, the MIC values can be lower when using the E-test than 
when using broth microdilution. Thus, E-test can better 
discriminate the susceptibility or resistance to these drugs 
among C. neoformans strains13.
The MIC distribution of the five antifungal drugs 
tested against C. neoformans was similar to that detected 
for isolates from AIDS patients from other regions14 and 
was also comparable to the susceptibility of isolates with 
the VNI genotype3. Regarding the epidemiological cutoff 
values (ECV) determined for the five antifungal drugs15,16, 
the C. neoformans var. grubii and C. gattii isolates 
evaluated here had antifungal MICs up to the respective 
ECV or immediately above it. No elevated MIC values 
that might characterize any of the isolates as resistant were 
detected. Thus, the isolates tested here in general were 
susceptible to drugs of clinical use, including amphotericin 
B, fluconazole and flucytosine. Similar results have been 
previously reported, showing only a small percentage 
of strains with reduced susceptibility, particularly to 
fluconazole and flucytosine7,17. The obtained data support 
the recommendation to perform the Cryptococcus spp. 
antifungal susceptibility test only in cases of isolates from 
relapsing/refractory cryptococcosis2. Comparison of C. 
neoformans infection in patients with and without AIDS 
revealed higher MICs for itraconazole and voriconazole in 
patients not infected with HIV. Cryptococcus isolated from 
Shangai patients with AIDS showed lower susceptibility 
to fluconazole than isolates from patients without AIDS18. 
Another study revealed that Cryptococcus isolates from 
non-HIV patients were less susceptible to flucytosine than 
isolates from AIDS patients19. The lack of specification 
of the isolate genotype and the heterogeneity of patients 
without AIDS make it difficult to re–conclude on eventual 
differences between isolates from patients with AIDS and 
without HIV infection regarding susceptibility to antifungal 
drugs. 
Separate analysis of AIDS cases did not show a 
difference in susceptibility between Cryptococcus isolates 
from patients with relapsing/refractory cryptococcosis and 
from patients with a good response to antifungal therapy. 
The MICs of Cryptococcus isolates obtained from the same 
patient before and after treatment failure were also similar, 
showing that reduced susceptibility to antifungal drugs is 
not an important factor for the progression of cryptococcosis 
to relapse and/or to a refractory state. The same observation 
was reported for isolates from South American patients20 
and those from Vietnam21. Conversely, in two other case 
series, the relapse of cryptococcosis was associated with 
lower susceptibility to fluconazole22,23. Cryptococcus spp. 
isolated from patients may show heteroresistance when 
exposed in vivo to azole drugs24.
The lethality of cryptococcosis in patients coinfected 
with HIV and treated with amphotericin and fluconazole was 
not related to the MIC of these drugs for the pretreatment 
isolates. The same conclusion was reported in studies on 
patients from other geographic areas13,20,25. Paradoxically, 
in Taiwanese patients, a MIC for fluconazole above 
8 µg mL-1was associated with the cure of cryptococcosis26. 
In conclusion, C. neoformans and C. gattii isolated in 
the present study proved, in general, to be susceptible to 
the drugs used in antifungal therapy. The MIC distribution 
of these drugs was not related to the progression of 
the infection to the condition of relapsing/refractory 
meningoencephalitis or to death due to fungal infection. 
ACKNOWLEDGMENTS
Erika Nascimento was the recipient of a fellowship from 
Fundação de Amparo à Pesquisa do Estado de São Paulo 
(FAPESP) for the execution of the present study (Protocol 
FAPESP 2010/51932-2).
REFERENCES
 1.  Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS - 100 
years after the discovery of Cryptococcus neoformans. Clin 
Microbiol Rev. 1995;8:515-48.
 2.  Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill 
JR, Hamill RJ, et al. Clinical practice guidelines for the 
management of cryptococcal disease: 2010 update by the 
Infectious Diseases Society of America. Clin Infect Dis. 
2010;50:291-322. 
 3.  Trilles L, Meyer W, Wanke B, Guarro J, Lazéra M. Correlation 
of antifungal susceptibility and molecular type within the 
Cryptococcus neoformans/C. gattii species complex. Med 
Mycol. 2012;50:328-32.
 4.  Figueiredo TP, Lucas RC, Cazzaniga RA, França CN, Segato 
F, Taglialegna R, et al. Antifungal susceptibility testing and 
genotyping characterization of Cryptococcus neoformans and 
gattii isolates from HIV-infected patients of Ribeirão Preto, 
São Paulo, Brazil. Rev Inst Med Trop Sao Paulo. 2016;58:69. 
Rev Inst Med Trop São Paulo. 2017;59:e49
Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients
Page 7 of 7
 5. Mahabeer Y, Chang CC, Naidu D, Dorasamy A, Lewin S, 
Ndung’u T, et al. Comparison of Etests and Vitek 2® to broth 
microdilution for the susceptibility testing of Cryptococcus 
neoformans. Diagn Microbiol Infect Dis. 2014;80:294-8.
 6.  Gullo FP, Rossi SA, Sardi JC, Teodoro VL, Mendes-Giannini 
MJ, Fusco-Almeida AM. Cryptococcosis: epidemiology, 
fungal resistance, and new alternatives for treatment. Eur J 
Clin Microbiol Infect Dis. 2013;32:1377-91.
 7.  Castanheira M, Messer SA, Rhomberg PR, Pfaller MA. Antifungal 
susceptibility  patterns of a global collection of fungal isolates: 
results of the SENTRY Antifungal Surveillance Program 
(2013). Diagn Microbiol Infect Dis. 2016;85:200-4.
 8.  Nascimento E, Vitali LH, Tonani L, Kress MR, Takayanagui 
OM, Martinez R. Refractory and/or relapsing cryptococcosis 
associated with acquired immune deficiency syndrome: clinical 
features, genotype, and virulence factors of Cryptococcus spp. 
isolates. Am J Trop Med Hyg. 2016;94:975-81. 
 9.  Clinical and Laboratory Standards Institute. M27-A3 : reference 
method for broth dilution antifungal susceptibility testing of 
yeasts. 3rd ed. Wayne: CLSI; 2008.
 10.  Hagen F, Hare Jensen R, Meis JF, Arendrup MC. Molecular 
epidemiology and in vitro antifungal susceptibility testing 
of 108 clinical Cryptococcus neoformans sensu lato and 
Cryptococcus gattii sensu lato isolates from Denmark. 
Mycoses. 2016;59:576-84.
 11.  Tewari A, Behera B, Mathur P, Xess I. Comparative analysis of 
the Vitek 2 antifungal susceptibility system and E-test with the 
CLSI M27-A3 broth microdilution method for susceptibility 
testing of Indian clinical isolates of Cryptococcus neoformans. 
Mycopathologia. 2012;173:427-33. 
 12. Chen SC, O’Donell ML, Gordon S, Gilbert GL. Antifungal 
susceptibility testing using E-test: comparison with the 
broth macrodilution technique. J Antimicrob Chemother. 
1996;37:265-73.
 13.  Dannaoui E, Abdul M, Arpin M, Michel-Nguyen A, Piens 
MA, Favel A, et al. Results obtained with various antifungal 
susceptibility testing methods do not predict early clinical 
outcome in patients with cryptococcosis. Antimicrob Agents 
Chemother. 2006;50:2464-70.
 14.  Souza LK, Fernandes OF, Kobayashi CC, Passos XS, Costa CR, 
Lemos JA, et al. Antifungal susceptibilities of clinical and 
environmental isolates of Cryptococcus neoformans in Goiânia 
city, Goiás, Brazil. Rev Inst Med Trop Sao Paulo. 2005;47:253-
6.
 15.  Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, Fothergill 
A, Fuller J, Hagen F, et al. Cryptococcus neoformans-
Cryptococcus gattii species complex: an international 
study of wild-type susceptibility endpoint distributions 
and epidemiological cutoff values for amphotericin B and 
flucytosine. Antimicrob Agents Chemother. 2012;56:3107-13.
 16.  Espinel-Ingroff A, Aller AI, Canton E, Castañón-Olivares LR, 
Chowdhary A, Cordoba S, et al. Cryptococcus neoformans-
Cryptococcus gattii species complex: an international 
study of wild-type susceptibility endpoint distributions and 
epidemiological cutoff values for fluconazole, itraconazole, 
posaconazole, and voriconazole. Antimicrob Agents 
Chemother. 2012;56:5898-906. 
 17.  Pan W, Khayhan K, Hagen F, Wahyuningsih R, Chakrabarti 
A, Chowdhary A, et al. Resistance of Asian Cryptococcus 
neoformans serotype A is confined to few microsatellite 
genotypes. PLoS One. 2012;7:e32868. 
 18.  Li M, Liao Y, Chen M, Pan W, Weng L. Antifungal susceptibilities 
of Cryptococcus species complex isolates from AIDS and 
non-AIDS patients in Southeast China. Braz J Infect Dis. 
2012;16:175-9.
 19.  Arsic Arsenijevic V, Pekmezovic MG, Meis JF, Hagen F. 
Molecular epidemiology and antifungal susceptibility 
of Serbian Cryptococcus neoformans isolates. Mycoses. 
2014;57:380-7. 
 20.  Agudelo CA, Muñoz C, Ramírez A, Tobón AM, de Bedout 
Bact C, Cano LE, et al. Response to therapy in patients 
with cryptococcosis and AIDS: association with in vitro 
susceptibility to fluconazole. Rev Iberoam Micol. 2015;32:214-
20.
 21.  Day JN, Duong VA, Chau TT, Hoang TN, Wolbers M. 
Relationship of susceptibility testing of Cryptococcus 
neoformans to survival and mycological clearance in HIV 
associated cryptococcal meningitis. Mycoses. 2014;57 Suppl 
1:106-7.
 22.  Davey KG, Szekely A, Johnson EM, Warnock DW. Comparison 
of a new commercial colorimetric microdilution method with 
a standard method for in-vitro susceptibility testing of Candida 
spp. and Cryptococcus neoformans. J Antimicrob Chemother. 
1998;42:439-44.
 23.  Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes 
G. Symptomatic relapse of HIV-associated cryptococcal 
meningitis after initial fluconazole monotherapy: the role of 
fluconazole resistance and immune reconstitution. Clin Infect 
Dis. 2006;43:1069-73.
 24.  Sionov E, Chang YC, Kwon-Chung KJ. Azole heteroresistance in 
Cryptococcus neoformans: emergence of resistant clones with 
chromosomal disomy in the mouse brain during fluconazole 
treatment. Antimicrob Agents Chemother. 2013;57:5127-30.
 25.  Smith KD, Achan B, Hullsiek KH, McDonald TR, Okagaki 
LH, Alhadab AA, et al. Increased antifungal drug resistance 
in clinical isolates of Cryptococcus neoformans in Uganda. 
Antimicrob Agents Chemother. 2015;59:7197-204.
 26.  Lee CH, Chang TY, Liu JW, Chen FJ, Chien CC, Tang YF, et al. 
Correlation of antifungal susceptibility with clinical outcomes 
in patients with cryptococcal meningitis. BMC Infect Dis. 
2012;12:361.
